The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
Abstract
PURPOSE: To evaluate the influence of cumulative dose, dose-intensity, single-dose level, and schedule of epirubicin on the risk of developing congestive heart failure (CHF) in patients with advanced breast cancer. PATIENTS AND METHODS: Four hundred sixty-nine consecutive anthracyline-naive patients with metastatic breast cancer were included. Only patients with cardiac failure according to New York Heart Association (NYHA) function class II or more were recorded as having CHF. For each patient, the following were calculated: the cumulative dose of epirubicin, mean dose-intensity (cumulative dose of epirubicin/duration of treatment), and single-dose level (cumulative dose of epirubicin/number of injections). RESULTS: Thirty-four patients (7.2%) developed CHF. The cumulative risk of cardiotoxicity was 4% at 900 mg/m2 and increased exponentially to 15% at 1,000 mg/m2. Irradiation against the mediastinum and thoracic spine increased the risk of CHF (P=.025), but dose-intensity, single-dose level, and schedule had no influence on the risk of developing CHF. Age, previous adjuvant irradiation (to the left or right hemithorax), and previous chemotherapy (cyclophosphamide, methotrexate, and fluorouracil [CMF]) were not risk factors. The median time to onset of CHF following the last dose of epirubicin was 57 days (range, 0 to 853). Among patients with CHF, 13 (38.2%) died of cardiac failure. The median survival time for all patients with CHF was 162 days (range, 0 to +1,957). Previous irradiation directly against the heart increased the risk of death due to cardiac failure and decreased the median survival time to 125 days (range, 0 to 336). CONCLUSION: The present large retrospective study of 469 patients substantiates previous results concerning the cardiotoxicity of epirubicin. A significantly increasing risk of CHF in patients who receive cumulative doses greater than 950 mg/m2 was established. The future recommended maximum cumulative dose of epirubicin should be 900 mg/m2 in patients with metastatic breast cancer. Previous irradiation against the heart leads to an increased risk of developing CHF with an accelerated course to death, which indicates an additive cardiotoxic effect of irradiation and epirubicin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
Cersosimo, R. J., & Hong, W. K. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.3.425 · Cited by 298
Jain, K. K., Casper, E. S., Geller, N. L., Hakes, T. B., Kaufman, R. J., Currie, V, Schwartz, W., Cassidy, C., Petroni, G. R., & Young, C. W. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.6.818 · Cited by 251
Adriamycin cardiotoxicity: a survey of 1273 patients.
Praga, C., Beretta, G., Pl, V., Gr, L., Pollini, C., Bonadonna, G., Canetta, R. M., Castellani, R., Villa, E., Cg, G., et al. (1979) · PubMed · Cited by 248
Plosker, G. L., & Faulds, D. (1993) · Drugs · doi:10.2165/00003495-199345050-00011 · Cited by 223
Cancer Clinical Trials: Methods and Practice.
Freedman, L. S., Buyse, M. E., Staquet, M., et al. (1985) · Biometrics · doi:10.2307/2531305 · Cited by 209
Hortobagyi, G. N., Frye, D., Buzdar, A. U., Ewer, M. S., Fraschini, G., Hug, V., Ames, F., Montague, E., Carrasco, C. H., Mackay, B., et al. (1989) · Cancer · doi:10.1002/1097-0142(19890101)63:1<37::aid-cncr2820630106>3.0.co;2-z · Cited by 198
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.
Torti, F. M., Bristow, M. R., Lum, B. L., Carter, S. K., Howes, A. E., Aston, D. A., Brown, B. W., Hannigan, J. F., Meyers, F. J., & Mitchell, E. P. (1986) · PubMed · Cited by 197
Pérez, D. J., Harvey, V. J., Robinson, B. A., Atkinson, C. H., Dady, P. J., Kirk, A. R., Evans, B. D., & Chapman, P. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.12.2148 · Cited by 116
Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer.
Nielsen, D. L., Jensen, J. B., Dombernowsky, P., Munck, O., Fogh, J., Brynjolf, I., Havsteen, H., & Hansen, M. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.11.1806 · Cited by 99
Self-citationPhase II study of doxorubicin versus epirubicin in advanced breast cancer.
Brambilla, C., Rossi, A., Bonfante, V., Ferrari, L., Villani, F., Crippa, F., & Bonadonna, G. (1986) · PubMed · Cited by 94
A Comparative Study of Doxorubicin and Epirubicin in Patients with Metastatic Breast Cancer
Hortobágyi, G. N., Yap, H. Y., Kau, S., Fraschini, G., Ewer, M. S., Chawla, S. P., & Benjamin, R. S. (1989) · American Journal of Clinical Oncology · doi:10.1097/00000421-198902000-00014 · Cited by 88
Cardiac morphologic and functional changes induced by epirubicin chemotherapy.
Dardir, M. D., Ferrans, V. J., Mikhael, Y., el-Grindy, M. S., el-Aasar, A. B., El‐Zawahry, H. M., Alling, D. W., Banks, S. M., & el-Mawla, N. G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.7.947 · Cited by 45
Monoclonal gammopathies in adult T-cell leukemia
Matsuzaki, H., Yamaguchi, K., Kagimoto, T., Nakai, R., Takatsuki, K., & Oyama, W. (1985) · Cancer · doi:10.1002/1097-0142(19850915)56:6<1361::aid-cncr2820560624>3.0.co;2-s · Cited by 36
Epirubicin or epirubicin and vindesine in advanced breast cancer. A Phase III study
Nielsen, D. L., Dombernowsky, P., Skovsgaard, T., Jensen, J. B., Andersen, E., Engelholm, S., & Hansen, M. (1990) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057748 · Cited by 27
Self-citationNeri, B., Pacini, P., Bartalucci, S., Moroni, F., Menchi, I., & Cappellini, M. D. (1989) · PubMed · Cited by 13
Cited by
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.07.012 · Cited by 1,795
Radiation Dose–Volume Effects in the Heart
Gagliardi, G., Constine, L. S., Moiseenko, V., Correa, C., Pierce, L. J., Allen, A. M., & Marks, L. B. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.04.093 · Cited by 1,227
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Metadata
- Authors
- Ryberg, M., Nielsen, D., Skovsgaard, T., Hansen, J., Jensen, B. V., & Dombernowsky, P.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-11
- Volume
- 16
- Issue
- 11
- Pages
- 3502-3508
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1796787464
- Cited by
- 289
- References
- 17
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.